FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System
This trial has no sites in United States.
It has sites in 14 countries. Choose a country to see its sites.
Trial details
- Who runs it
- Medtronic Cardiovascular
- Trial code
- NCT03417011
- Record updated
- 9 September 2025
- Original description
Prospective, single-arm, multi-center, interventional post-market study. After signing informed consent, eligible subjects will be implanted with the CE marked Evolut™ PRO system.Read full original descriptionShow less
Prospective, single-arm, multi-center, interventional post-market study. After signing informed consent, eligible subjects will be implanted with the CE marked Evolut™ PRO system.
The investigation purpose is to evaluate the acute and long term clinical performance and safety of Evolut™ PRO in a routine hospital setting in patients with symptomatic native aortic valve stenosis or a stenosed, insufficient, or combined surgical bioprosthetic valve failure necessitating valve replacement within the approved intended use in local geography.
Inclusion: Symptomatic native aortic valve stenosis or a stenosed, insufficient, or combined surgical bioprosthetic valve failure necessitating valve replacement; High or greater risk for surgical aortic valve replacement as estimated by the heart team OR, 75 years or older and at intermediate risk for surgical AVR (STS risk score ≥4% or with an estimated hospital mortality ≥4% as assessed by the heart team); Acceptable candidate for treatment with the Evolut™ PRO system in conformity with the Instructions for Use and the local regulations; Able and willing to return to the implanting site at the following follow-up visits: 1-year, 3-year and 5-year; Written informed consent obtained without assistance from a legal representative prior to enrollment in the study.
Exclusion: Need for emergency surgery for any reason; Known hypersensitivity or contraindication to aspirin, heparin (HIT/HITTS) and bivalirudin, ticlopidine, clopidogrel, Nitinol (Titanium or Nickel), or sensitivity to contrast media, which cannot be adequately premedicated; Preexisting mechanical heart valve in aortic position; Ongoing sepsis, including active endocarditis; Anatomically not suitable for the Evolut™ PRO system; Estimated life expectancy of less than 1 year; Participating in another trial that may influence the outcome of this study; Inability to understand and respond to the quality of life questionnaire.